A Phase 3 interventional study of HX575 epoetin alfa and US-licensed epoetin alfa in Anemia and Chronic Kidney Disease (CKD), sponsored by Sandoz. Completed at 52 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-07-02.
Sponsored by Sandoz (formerly part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Anemia by Novartis — 1 open to participants now, 2 under way, 2 of them phase 3. Anemia · Novartis.
Among the 19 studies in Anemia by Novartis, this one is the 4th largest by enrollment of the 17 interventional ones that give a count, is the only one that started in 2012, is one of 12 in phase 3, and was the 11th registered.
1,810 studies on the registry are indexed under Anemia; 214 are open to participants now.
Browse Anemia studies →1 of the 19 studies in Anemia by Novartis is open now, in 6 countries. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in United States, Brazil, Colombia and 3 more countries
Ages 2–18
By country, each count listing its studies:
Of the 121 Anemia studies recruiting now, 67 (55%) set no upper age limit and 36 (30%) stop at 75 or younger; 33 take children under 18; 22 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 1 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 435 is above the median of 117 across 1,336 interventional studies indexed under Anemia.
Median enrollment 97 across the 17 interventional studies, 1,097 across the 2 observational. Of the 16 that completed or were terminated, 11 (69%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Sandoz, one of the names counted as Novartis. Under that name alone:
Sandoz is the lead sponsor of 139 studies on the registry; none are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 6 (55%) have results posted.
1 of the studies in Anemia by Novartis that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04747613Phase 3Novartis PharmaceuticalsLong-term Safety and Tolerability of Iptacopan in Patients With Paroxysmal Nocturnal Hemoglobinuria | 2027-10-18 |
Add it to your calendar (.ics) → With an account.
Among the 19 studies in Anemia by Novartis, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to show biosimilarity of HX575 epoetin alfa with the US licensed reference product Epogen®/Procrit® when applied subcutaneously. This study is intended to generate data supporting that the efficacy and safety under treatment with HX575 and Epogen®/Procrit® are comparable.
This is a randomized, double-blind, parallel-group, multicenter study to evaluate the efficacy and safety of HX575 epoetin alfa vs. US-licensed epoetin alfa (Epogen®/Procrit®) in the treatment of anemia associated with chronic kidney disease (CKD).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other In-/Exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HX575, recombinant human epoetin alfa
Drug: HX575 epoetin alfa
US-licensed recombinant human epoetin alfa
Drug: US-licensed epoetin alfa
Solution for subcutaneous injection. The drug is administered subcutaneously at least once per week over 52 weeks. The dose will be individually titrated to maintain hemoglobin levels between 10 to 11 g/dL.
Also known as: Binocrit® (Europe), Epoetin alfa HEXAL® (Europe), Abseamed® (Europe)
Solution for subcutaneous injection.
Also known as: Epogen®, Procrit®
Mean Absolute Change in Hemoglobin Levels Between the Screening/Baseline Period (Week -4 to Day 1) and the Evaluation Period (Week 21-28)
Response to epoetin alfa in anemic patients with chronic renal failure is manifested by increased hematocrit, hemoglobin, reduced transfusion requirements and increase in quality of life. Hemoglobin (laboratory haematology parameter) is the primary endpoint of the study .
Time frame: Week -4 to Day1 and Week 21-28
Change in Mean Hb Level Between Baseline (Week -4 to Day1) and Evaluation Period (Week 21-28)
Response to epoetin alfa in anemic patients with chronic renal failure is manifested by increased hematocrit, hemoglobin, reduced transfusion requirements and increase in quality of life. Hemoglobin (laboratory haematology parameter) is the primary endpoint of the study .
Time frame: Week -4 to Day1 and Week 21-28
Mean Weekly Dose During Evaluation Period (Week 21-28)
Mean weekly study drug dose during evaluation period (Week 21-28)
Time frame: Week 21-28
Incidence of Antibody Formation Against Epoetin
Number of patients with positive antidrug antibody (ADA) finding at any time during their treatment period. Count includes 2 patients (1 in each arm) that already had a positive ADA Baseline finding. ADA testing performed by by Radio-Immuno-Precipitation assay. No patient developed neutralizing antibodies.
Time frame: 52 weeks
| Milestone | HX575 Epoetin Alfa | US-licensed Epoetin Alfa |
|---|---|---|
| Started | 217 | 218 |
| Completed | 173 | 161 |
| Not completed | 44 | 57 |
| Withdrew: Withdrawal by subject | 15 | 22 |
| Withdrew: Kidney transplantation | 7 | 7 |
| Withdrew: Bindinging anti-epo antibodies | 6 | 2 |
| Withdrew: Protocol violation | 6 | 7 |
| Withdrew: Change in dialysis modality | 2 | 1 |
| Withdrew: Physician decision | 0 | 2 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Adverse event | 1 | 6 |
| Withdrew: Death | 5 | 8 |
| Withdrew: Non-compliance | 2 | 1 |
Response to epoetin alfa in anemic patients with chronic renal failure is manifested by increased hematocrit, hemoglobin, reduced transfusion requirements and increase in quality of life. Hemoglobin (laboratory haematology parameter) is the primary endpoint of the study .
| g/dL | HX575 Epoetin Alfa | US-licensed Epoetin Alfa |
|---|---|---|
| Mean Absolute Change in Hemoglobin Levels Between the Screening/Baseline Period (Week -4 to Day 1) and the Evaluation Period (Week 21-28) | -0.0960 ± 0.0575 | -0.0035 ± 0.0573 |
Response to epoetin alfa in anemic patients with chronic renal failure is manifested by increased hematocrit, hemoglobin, reduced transfusion requirements and increase in quality of life. Hemoglobin (laboratory haematology parameter) is the primary endpoint of the study .
| g/dL | HX575 Epoetin Alfa | US-licensed Epoetin Alfa |
|---|---|---|
| Baseline period | 10.53 ± 0.635 | 10.50 ± 0.615 |
| Evaluation period | 10.42 ± 0.826 | 10.51 ± 0.873 |
| Change from baseline period to evaluation period | -0.11 ± 1.011 | 0.01 ± 0.953 |
Mean weekly study drug dose during evaluation period (Week 21-28)
| international units | HX575 Epoetin Alfa | US-licensed Epoetin Alfa |
|---|---|---|
| Mean Weekly Dose During Evaluation Period (Week 21-28) | 5876.5 ± 5785.50 | 5804.0 ± 6343.70 |
Number of patients with positive antidrug antibody (ADA) finding at any time during their treatment period. Count includes 2 patients (1 in each arm) that already had a positive ADA Baseline finding. ADA testing performed by by Radio-Immuno-Precipitation assay. No patient developed neutralizing antibodies.
| Participants | HX575 Epoetin Alfa | US-licensed Epoetin Alfa |
|---|---|---|
| Incidence of Antibody Formation Against Epoetin | 7 | 2 |
Collected over Adverse events were collected from the date of informed consent until the end of the treatment period, for approximately 1 year.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| HX575 Epoetin Alfa | 5/217 (2.3%) | 91/217 (41.9%) | 112/217 (51.6%) |
| US-licensed Epoetin Alfa | 11/218 (5%) | 90/218 (41.3%) | 123/218 (56.4%) |
| Event | HX575 Epoetin Alfa | US-licensed Epoetin Alfa |
|---|---|---|
| PneumoniaInfections and infestations | 9/217 | 10/218 |
| Cardiac failure congestiveCardiac disorders | 8/217 | 4/218 |
| HyperkalaemiaMetabolism and nutrition disorders | 8/217 | 7/218 |
| Fluid overloadMetabolism and nutrition disorders | 6/217 | 8/218 |
| CellulitisInfections and infestations | 7/217 | 7/218 |
| Atrial fibrillationCardiac disorders | 3/217 | 7/218 |
| HypoglycaemiaMetabolism and nutrition disorders | 3/217 | 7/218 |
| Non-cardiac chest painGeneral disorders | 6/217 | 2/218 |
| AnaemiaBlood and lymphatic system disorders | 4/217 | 6/218 |
| PeritonitisInfections and infestations | 5/217 | 3/218 |
| Event | HX575 Epoetin Alfa | US-licensed Epoetin Alfa |
|---|---|---|
| HypertensionVascular disorders | 24/217 | 27/218 |
| Upper respiratory tract infectionInfections and infestations | 12/217 | 22/218 |
| DiarrhoeaGastrointestinal disorders | 21/217 | 19/218 |
| NauseaGastrointestinal disorders | 17/217 | 20/218 |
| FallInjury, poisoning and procedural complications | 13/217 | 18/218 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 12/217 | 16/218 |
| Arteriovenous fistula site complicationInjury, poisoning and procedural complications | 15/217 | 11/218 |
| HeadacheNervous system disorders | 15/217 | 15/218 |
| VomitingGastrointestinal disorders | 10/217 | 15/218 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 9/217 | 15/218 |
| Age, Continuous(years) | HX575 Epoetin Alfa | US-licensed Epoetin Alfa | Total |
|---|---|---|---|
| Mean | 59.8 ± 13.76 | 57.6 ± 13.40 | 58.7 ± 13.61 |
| Sex: Female, Male(Participants) | HX575 Epoetin Alfa | US-licensed Epoetin Alfa | Total |
|---|---|---|---|
| Female | 82 | 103 | 185 |
| Male | 135 | 115 | 250 |
| Ethnicity (NIH/OMB)(Participants) | HX575 Epoetin Alfa | US-licensed Epoetin Alfa | Total |
|---|---|---|---|
| Hispanic or Latino | 95 | 93 | 188 |
| Not Hispanic or Latino | 122 | 125 | 247 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | HX575 Epoetin Alfa | US-licensed Epoetin Alfa | Total |
|---|---|---|---|
| American Indian or Alaska Native | 11 | 5 | 16 |
| Asian | 6 | 13 | 19 |
| Native Hawaiian or Other Pacific Islander | 4 | 0 | 4 |
| Black or African American | 57 | 72 | 129 |
| White | 139 | 128 | 267 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | HX575 Epoetin Alfa | US-licensed Epoetin Alfa | Total |
|---|---|---|---|
| United States | 217 | 218 | 435 |
| Height(cm) | HX575 Epoetin Alfa | US-licensed Epoetin Alfa | Total |
|---|---|---|---|
| Mean | 167.2 ± 10.17 | 166.0 ± 10.33 | 166.6 ± 10.26 |
| Weight(kg) | HX575 Epoetin Alfa | US-licensed Epoetin Alfa | Total |
|---|---|---|---|
| Mean | 82.8 ± 20.75 | 86.5 ± 24.32 | 84.6 ± 22.66 |
| BMI(kg/m^2) | HX575 Epoetin Alfa | US-licensed Epoetin Alfa | Total |
|---|---|---|---|
| Mean | 29.55 ± 6.872 | 31.41 ± 8.783 | 30.48 ± 7.933 |
5 further baseline measures are reported on the registry.
Plan to share: Undecided
The record gives a start of Sep 2012, a primary completion of May 2014 and a completion of Mar 2015. It does not say whether these dates are actual or estimated.
Results were first posted in May 2017, 3 years after primary completion. A results delay was requested in May 2015.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.